AJP - GI Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Am J Physiol Gastrointest Liver Physiol (May 8, 2008). doi:10.1152/ajpgi.00047.2008
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
295/1/G187    most recent
00047.2008v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shi, X.-Z.
Right arrow Articles by Sarna, S. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shi, X.-Z.
Right arrow Articles by Sarna, S. K.
Submitted on January 30, 2008
Accepted on May 5, 2008

GENE THERAPY of Cav1.2 CHANNEL WITH VIP AND VIP RECEPTOR AGONISTS AND ANTAGONISTS: A NOVEL APPROACH TO DESIGNING PRO-MOTILITY AND ANTI-MOTILITY AGENTS

Xuan-Zheng Shi1 and Sushil K. Sarna2*

1 Gastroenterology, The University of Texas Medical Branch, Galveston, Galveston, Texas, United States
2 Division of Gastroenterology, University of Texas Medical Branch at Galveston, Galveston, Texas, United States

* To whom correspondence should be addressed. E-mail: sksarna{at}utmb.edu.

Recent findings show that the enteric neurotransmitter VIP enhances gene transcription of the {alpha}1C subunit of Cav1.2 (L-type) Ca2+ channels in primary cultures of the human colonic circular smooth muscle cells and circular smooth muscle strips. In this study, we investigated whether systemic infusion of VIP at low concentrations in intact animals enhances the gene transcription and protein expression of these channels to accelerate colonic transit. We also investigated whether similar systemic infusions of VPAC1/2 receptor antagonist retards colonic transit by suppressing the gene expression of the {alpha}1C subunit. We found that the systemic infusion of VIP for seven days by a surgically implanted osmotic pump enhances the gene and protein expression of the {alpha}1C subunit, and circular muscle contractility in the proximal and the middle rat colons, but not the distal colon. A similar systemic infusion of VPAC1/2 receptor antagonist suppresses the expression of the {alpha}1C subunit and circular smooth muscle contractility in the proximal and the middle colons. The VIP infusion also accelerates colonic transit and pellet defecation by rats, whereas, the infusion of VPAC1/2 receptor antagonist retards colonic transit and pellet defecation. VPAC1 receptors, but not VPAC2 receptors, mediate the above gene-transcription induced promotility effects of VIP. We conclude that VIP and VPAC1 receptor agonists may serve as potential promotility agents in constipation-like conditions, while VPAC receptor antagonists may serve as potential anti-motility agents in diarrhea-like conditions produced by enhanced motility function.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 1977 by the American Physiological Society.